Loading
PDBj
MenuPDBj@FacebookPDBj@TwitterPDBj@YouTubewwPDB FoundationwwPDB
RCSB PDBPDBeBMRBAdv. SearchSearch help

4L94

Crystal structure of Human Hsp90 with S46

Summary for 4L94
Entry DOI10.2210/pdb4l94/pdb
Related4L8Z 4L90 4L91 4L93
DescriptorHeat shock protein HSP 90-alpha, (4-hydroxyphenyl)(4-methylpiperazin-1-yl)methanone (3 entities in total)
Functional Keywordsatp hydrolysis, hsp90n-hsp90n inhibitor complex, chaperone-chaperone inhibitor complex, chaperone/chaperone inhibitor
Biological sourceHomo sapiens (human)
Cellular locationCytoplasm: P07900
Total number of polymer chains1
Total formula weight25877.04
Authors
Li, J.,Ren, J.,Yang, M.,Xiong, B.,He, J. (deposition date: 2013-06-18, release date: 2014-06-18, Last modification date: 2023-11-08)
Primary citationRen, J.,Li, J.,Wang, Y.,Chen, W.,Shen, A.,Liu, H.,Chen, D.,Cao, D.,Li, Y.,Zhang, N.,Xu, Y.,Geng, M.,He, J.,Xiong, B.,Shen, J.
Identification of a new series of potent diphenol HSP90 inhibitors by fragment merging and structure-based optimization
Bioorg.Med.Chem.Lett., 24:2525-2529, 2014
Cited by
PubMed Abstract: Heat shock protein 90 (HSP90) is a molecular chaperone to fold and maintain the proper conformation of many signaling proteins, especially some oncogenic proteins and mutated unstable proteins. Inhibition of HSP90 was recognized as an effective approach to simultaneously suppress several aberrant signaling pathways, and therefore it was considered as a novel target for cancer therapy. Here, by integrating several techniques including the fragment-based drug discovery method, fragment merging, computer aided inhibitor optimization, and structure-based drug design, we were able to identify a series of HSP90 inhibitors. Among them, inhibitors 13, 32, 36 and 40 can inhibit HSP90 with IC50 about 20-40 nM, which is at least 200-fold more potent than initial fragments in the protein binding assay. These new HSP90 inhibitors not only explore interactions with an under-studied subpocket, also offer new chemotypes for the development of novel HSP90 inhibitors as anticancer drugs.
PubMed: 24751441
DOI: 10.1016/j.bmcl.2014.03.100
PDB entries with the same primary citation
Experimental method
X-RAY DIFFRACTION (1.649 Å)
Structure validation

226707

数据于2024-10-30公开中

PDB statisticsPDBj update infoContact PDBjnumon